BofA defends Hims & Hers as Lilly combats compounded GLP-1s #HIMS #LLY #GLP1 [ljnQ2z7N0]

BofA defends Hims & Hers as Lilly combats compounded GLP-1s #HIMS #LLY #GLP1 [ljnQ2z7N0]

Last month, Hims & Hers launched discounted compounded GLP-1s with semaglutide, the active ingredient in Ozempic and Wegovy, at a sharp discount to branded products. On Thursday, Lilly sued entities selling compounded tirzepatide labeled as Mounjaro and Zepbound. While HIMS expects to launch compounded tirzepatide within the next few months, BofA analyst Allen Lutz said he doesn’t think the company is making misleading claims about its GLP-1 products. “Looking at HIMS’ website, the company does not appear to make misleading claims about the facilities within which the compounded products are manufactured or the products themselves,” he added, reaffirming the Buy rating and $26 target on the stock.

Related Videos :

• 8 Best Juices for your Body [7jxyKgXP5]
• Is Coffee bad for PCOS Weight Loss? ☕#pcos #weightloss [qSRYs6Dm4]
• Quick dinner recipe #dinner #lunch #shorts #nonveg #homemade #deliciious #food [uPSeb2FpB]
• 🧘 Yoga for Weight Management & Radiant Skin ⭐️ Natural Wellness Tips. [yIzwt6AbP]
• Abby Lee Miller is disgusted with us! 👀 [7JWwlbvMS]